PET/MRI在高级别脑胶质瘤放射治疗中的应用

doi:10.11904/j.issn.1002-3070.2017.06.016

Abstract

Abstract: Regulation of calcineurin 1(RCAN1),as an endogenous protein that interacts with calcineurin(CaN),widely expresses in many malignant tumor cells,such as small cell lung cancer,thyroid cancer,leukemia,liver cancer,malignant glioma,endometrial adenocarcinoma and so on.In recent years,many studies have been shown that when RCAN1 is highly expressed,it can inhibit tumor proliferation,differentiation,invasion and metastasis by a variety of ways,thereby inhibiting tumor progression.These findings play an important role in the survival and prognosis of patients,and provide a theoretical basis for the treatment and intervention of malignant tumors.

Key words: High-grade glioma, Positron emission tomography, Magnetic resonance imaging, Radiotherapy

CLC Number:

R739.41

ZHAO Yongrui, XU Jiankun. The application of PET/MRI in high-grade glioma by radiotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 564-568.

References

1 Louis DN,Ohgaki H,Wiestler OD,et al.The 2007 WHO classification of tumours of the central nervous system[J].Acta Neuropathol,2007,114(2):97-109.
2 Ahmed R,Oborski MJ,Hwang M,et al.Malignant gliomas:current perspectives in diagnosis,treatment,and early response assessment using advanced quantitative imaging methods[J].Cancer Manag Res,2014,6:149-170.
3 Mertens K,Acou M,Van Hauwe J,et al.Validation of ¹⁸F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas:a stereotactic PET and MRI study[J].Clin Nucl Med,2013,38(7):495-500.
4 Sweeney R,Polat B,Samnick S,et al.O-(2-[¹⁸F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy[J].Ann Nucl Med,2014,28(2):154-162.
5 Miyake K,Shinomiya A,Okada M,et al.Usefulness of FDG,MET and FLT-PET studies for the management of human gliomas[J].J Biomed Biotechnol,2012,2012:205818.
6 Collet S,Valable S,Constans JM,et al.[¹⁸F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas[J].Neuroimage Clin,2015,8:448-454.
7 Schwarzenberg J,Czernin J,Cloughesy TF,et al.3′-deoxy-3′-¹⁸F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab[J].J Nucl Med,2012,53(1):29-36.
8 Bell C,Dowson N,Puttick S,et al.Increasing feasibility and utility of(¹⁸)F-FDOPA PET for the management of glioma[J].Nucl Med Biol,2015,42(10):788-795.
9 Ledezma CJ,Chen W,Sai V,et al.¹⁸F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas:initial experience[J].Eur J Radiol,2009,71(2):242-248.
10 Ullrich RT,Kracht L,Brunn A,et al.Methyl-L-¹¹C-methionine PET as a diagnostic marker for malignant progression in patients with glioma[J].J Nucl Med,2009,50(12):1962-1968.
11 Sharma R,D′Souza M,Jaimini A,et al.A comparison study of ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors[J].Indian J Nucl Med,2016,31(2):93-102.
12 Stall B,Zach L,Ning H,et al.Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas[J].Radiat Oncol,2010,5:5-11.
13 Wen PY,Macdonald DR,Reardon DA,et al.Updated response assessment criteria for high-grade gliomas:response assessment in neuro-oncology working group[J].J Clin Oncol,2010,28(11):1963-1972.
14 Cabrera AR,Kirkpatrick JP,Fiveash JB,et al.Radiation therapy for glioblastoma:Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline[J].Pract Radiat Oncol,2016,6(4):217-225.
15 Lucas JJ,Serrano N,Kim H,et al.¹¹C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma[J].J Neurooncol,2017,132(1):163-170.
16 Navarria P,Reggionri G,Pessina F,et al.Investigation on the role of integrated PET/MRI for target volume and radiotherapy planning in patients with high grade glioma[J].Radiother Oncol,2014,112(3):425-429.
17 Grosu AL,Weber WA,Riedel E,et al.L-(methyl-¹¹C)methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy[J].Int J Radiat Oncol Biol Phys,2005,63(1):64-74.
18 闫文明,王宏伟,郁志龙,等.生物靶区定位在胶质瘤术后放射治疗的临床价值研究[J].实用癌症杂志.2016,31(8):1349-1351.
19 Munck ARP,Costa J,Engelholm SA,et al.Impact of[¹⁸F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma[J].Neuro Oncol,2015,17(5):757-763.
20 Piroth MD,Holy R,Pinkawa M,et al.Prognostic impact of postoperative,pre-irradiation ¹⁸F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy[J].Radiother Oncol,2011,99:218-224.
21 Niyazi M,Geisler J,Siefert A,et al.FET-PET for malignant glioma treatment planning[J].Radiother Oncol,2011,99(1):44-48.
22 Chao ST,Suh JH,Raja S,et al.The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery[J].Int J Cancer,2001,96(3):191-197.
23 Garcia JR,Cozar M,Baquero M,et al.The value of ¹¹C-methionine PET in the early differentiation between tumour recurrence and radionecrosis in patients treated for a high-grade glioma and indeterminate MRI[J].Rev Esp Med Nucl Imagen Mol,2016,2017,36(2):85-90.
24 Shishido H,Kawai N,Miyake K,et al.Diagnostic value of ¹¹C-Methionine(MET)and ¹⁸F-Fluorothymidine(FLT)positron emission tomography in recurrent high-grade gliomas;differentiation from treatment-induced tissue necrosis[J].Cancers,2012,4(1):244-256.
25 Jansen NL,Schwartz C,Graute VA,et al.Prediction of oligodendroglial histology and LOH 1p/19q using dynamic[¹⁸F]FET-PET imaging in intracranial WHO grade II and III gliomas[J].Neuro Oncol,2012,14(12):1473-1480.
26 Niyazi M,Jansen N,Ganswindt U,et al.Re-irradiation in recurrent malignant glioma:prognostic value of [¹⁸F]FET-PET[J].J Neuron Oncol,2012,110(3):389-395.
27 Galldiks N,Rapp M,Stoffels G,et al.Response assessment of bevacizumab in patients with recurrent malignant glioma using [¹⁸F]Fluoroethyl-1-tyrosine PET in comparison to MRI[J].Eur J Nucl Med Mol Imaging,2013,40(1):22-33.
28 Galldiks N,Stoffels G,Ruge MI,et al.Role of O-(2-¹⁸F-Fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma[J].J Nucl Med,2013,54(12):2046-2054.
29 Jena A,Taneja S,Gambhir A,et al.Glioma recurrence versus radiation necrosis:Single-session multiparametric approach using simultaneous O-(2-¹⁸F-Fluoroethyl)-L-tyrosine PET/MRI[J].Clin Nucl Med,2016,41(5):228-236.

[1]	LI Jiaqi,LUAN Jinwei,ZHANG Yu,LI Xianglan. Analysis of clinicopathological features,recurrence and metastasis in 763 triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 244-249.
[2]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[3]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[4]	ZHANG Pan, ZHANG Di, DAI Xiaobo. Advanced in re-radiotherapy for recurrent nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 92-96.
[5]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[6]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[7]	LIU Guohui, GU Anxin, YIN Hongtao, CAO Yang, HE Yunlong, WANG Chunbo, E Mingyan. Protosappanin A increases the sensitivity of gastric cancer SGC-7901 cells to radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 500-505.
[8]	WANG Wei, SUN Peng, LIU Yanshu, LI Lulu, LIU Zhilan, ZHANG Yuanli, ZHANG Yujing. Functional magnetic resonance imaging in the accurate diagnosis of gliomas [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 524-527.
[9]	LUO Jianing, HAO Chuncheng, ZHANG Jianxin, LU Jiangyue, GE Xiaofeng. Effect of postoperative adjuvant radiotherapy on prognosis of triple-negative breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 411-416.
[10]	CHENG Jing,CHEN Ji,WANG Xiaoyong,ZHANG Junhong,ZHOU Fuxiang,XIE Conghua. Changes in the volume of chest muscles and its clinical significance in thoracic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 123-130.
[11]	QU Yuanyuan,XU Xiangying,ZHUANG Ming,YIN Hongtao,HU Songliu,WANG Chunbo,CAO Yang. Nimotuzumab enhances the radiosensitivity of lung cancer A549 cells in vitro [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 497-501.
[12]	YANG Meijian, BAO Yingna, ZHAO Jianguo. Advances in neoadjuvant therapy of rectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 453-457.
[13]	LIU Wei,LI Huiyan. Progress in relationship between epidermal growth factor receptor and radiosensitivity [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 275-278.
[14]	LU Pei′ou, WANG Wenzhi, LI Yingci, LIU Rui, HU Yumin, YU Lijuan. The clinical value of ¹⁸F-FDG PET/CT for the patients with ascites of unknown causes [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 114-117.
[15]	SHI Manru, E Mingyan. The influences of breast cancer subtypes on reactivity and radiosensitisvity of radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 154-157.

The application of PET/MRI in high-grade glioma by radiotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments